A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke

Stopped early · Phase 2

Conditions studied: Stroke

In brief

The purpose of this study is to determine whether a new research medication is effective and safe for the treatment of acute stroke when given within 6 hours of the onset of stroke.

Key facts

Study ID

NCT00073476

Run by

Pfizer

People needed

300

Starts

2003-09-01

Expected to finish

2005-02-01

Last updated by the study team

2006-06-22

Who can join

Age: 40 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males \& females age 40-90 years
• Enrolled in study within 6 hours of onset of stroke symptoms
• Willing to sign informed consent form
• No significant disabilities prior to stroke

You may not qualify if…

• Treatment with t-PA (tissue plasminogen activator)
• Premorbid modified rankin scale score of 2 or more

Where it is running

• Pfizer Investigational Site — La Mesa, California, United States
• Pfizer Investigational Site — Atlanta, Georgia, United States
• Pfizer Investigational Site — Fort Wayne, Indiana, United States
• Pfizer Investigational Site — Fort Wayne, Indiana, United States
• Pfizer Investigational Site — Louisville, Kentucky, United States
• Pfizer Investigational Site — Salisbury, North Carolina, United States
• Pfizer Investigational Site — Dayton, Ohio, United States
• Pfizer Investigational Site — Dayton, Ohio, United States
• Pfizer Investigational Site — Dayton, Ohio, United States
• Pfizer Investigational Site — Dayton, Ohio, United States
• Pfizer Investigational Site — Allentown, Pennsylvania, United States
• Pfizer Investigational Site — Philadelphia, Pennsylvania, United States
• Pfizer Investigational Site — Tartu, Estonia
• Pfizer Investigational Site — Bad Neustadt an der Saale, Germany
• Pfizer Investigational Site — Freiburg im Breisgau, Germany
• Pfizer Investigational Site — Leipzig, Germany
• Pfizer Investigational Site — Lübeck, Germany
• Pfizer Investigational Site — Budapest, Hungary
• Pfizer Investigational Site — Győr, Hungary
• Pfizer Investigational Site — Pavia, Italy
• Pfizer Investigational Site — Perugia, Italy
• Pfizer Investigational Site — Coimbra, Portugal
• Pfizer Investigational Site — Lisbon, Portugal
• Pfizer Investigational Site — Singapore, Singapore
• Pfizer Investigational Site — Singapore, Singapore

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.